CancerQuest | Interview with Dr. David Fry

Dr. David Fry
Roche Research Center
Hoffmann-La Roche Inc.

David Fry is a research scientist at the Hoffmann-La Roche Research Center in Nutley, NJ. In this interview, Dr. Fry discusses his work on the development of cancer drugs that target protein:protein interactions. Specifically, his work is directed at disrupting the interaction between the p53 and MDM2 proteins.

Questions and Answers

	About Dr. Fry
	How did you first get involved in medical research?
	How did you begin working specifically on cancer?
	How do you decide what to target in cancer cells?
	Can you tell us more about your approach to developing drugs that can block the p53:MDM2 interaction?
	How do you go about deciding which chemicals to test?
	Where do you get the chemicals to test?
	How do you test the new candidate drugs?
	Have you had any success in identifying drug candidates?
	Once you have identified a chemical, how do you refine it to make it a better drug?
	Are you able to predict which chemicals would have side effects if they became drugs?
	Do you use computers to help with drug design?
	Do you see an increasing role for computers in drug development?
	What new tools are being used to help identify new drugs?